Investor Presentaiton

With the acquisition, Coloplast adds a long-term growth business and enters the attractive biologics segment Kerecis - a sustainable business with a clinically differentiated technology and a great fit to Coloplast... ...well-positioned for long-term value creation 48 Shared mission of making life easier for patients by bringing innovative and life- changing technologies to the market Patented and clinically differentiated technology platform based on minimally processed fish skin, which supports effective wound healing Emerging category leader, allowing Coloplast to enter the fast-growing US-centric biologics segment Strong cultural fit, rooted in shared Nordic origins and sustainability leadership. Unique waste-to-value proposition, key to a cost-efficient production setup Coloplast's industry leading, scalable infrastructure and complimentary geographical footprint to support and enable Kerecis' continued growth and expansion Growth outlook: Accretive to Coloplast group organic growth with ~1%-point as of FY 2024/25 CAGR of -30% expected over the next three years until FY 2025/26 Profitability outlook: Strong potential for profitability expansion, driven by continued growth and scalability. Gross margin accretive EBIT margin of around 20% expected in FY 2025/26. In the following years, the margin is expected to be in line with Coloplast's long-term guidance of more than 30% Increasingly EPS accretive from FY 2026/27 Coloplast

View entire presentation